Literature DB >> 417

Simultaneous determination of propranolol and 4-hydroxypropranolol in plasma by mass fragmentography.

T Walle, J Morrison, K Walle, E Conradi.   

Abstract

A quantitative method for the simultaneous determination of propranolol and its active metabolite 4-hydroxypropranolol in human plasma is described. Plasma samples are extracted at pH 9.6 with ethyl acetate after the addition of sodium bisulphite and the internal standard oxprenolol. The extracts are derivatized with trifluoroacetic anhydride before separation on a gas chromatograph--mass spectrometer. Detection and quantitation of the trifluoroacetyl derivatives are made by single-ion monitoring. The minimum detectable concentration of propranolol is 1 ng/ml and of 4-hydroxypropranolol 5 ng/ml using 1-ml plasma samples. No interferences from normal plasma constituents or from drugs commonly prescribed together with propranolol were detected.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 417     DOI: 10.1016/s0021-9673(01)92000-x

Source DB:  PubMed          Journal:  J Chromatogr


  4 in total

1.  Partial metabolic clearances as determinants of the oral bioavailability of propranolol.

Authors:  T Walle; U K Walle; L S Olanoff; E C Conradi
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

2.  Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.

Authors:  S A Bai; U K Walle; T Walle
Journal:  J Pharmacokinet Biopharm       Date:  1985-06

3.  Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy.

Authors:  L Wong; R L Nation; W L Chiou; P K Mehta
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

4.  An improved HPLC-MS/MS method for simultaneous quantification of propranolol and its two phase I metabolites in plasma of infants with hemangioma and its application to a comparative study of plasma concentrations.

Authors:  Huan He; Li Li; Libo Zhao; Ning Sun; Meng Zhang; Ying Cheng; Lu Yu; Lin Ma; Xiaoling Wang
Journal:  RSC Adv       Date:  2018-11-07       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.